Cancer Center– A Cancer Center Designated by
the National Cancer Institute

Clinical Trials in the Category "Hodgkin Disease"

Drug Intervention Trials that are Recruiting

Study Title
 Principal Investigator Disease Category
A Pivotal Open-Label Trial of SGN-35 for Hodgkin Lymphoma Sandra Jeane Horning
 Lymphoma, Hodgkin Disease
Hodgkin Disease
Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Lymphoproliferative Malignancies Ranjana Hira Advani
 Lymphoma, Hodgkin Disease
Hodgkin Disease
Lymphoma, Non-Hodgkin
A Phase I Dose Escalation Study of Weekly SGN-35 Alone and in Combination With Gemcitabine in HL Sandra Jeane Horning
 Lymphoma, Hodgkin Disease
Hodgkin Disease
Blood Cancer
Therapy for Pediatric Hodgkin Lymphoma Michael Link
 Lymphoma, Hodgkin Disease
Hodgkin Disease
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma Sandra Jeane Horning
 Lymphoma
Lymphoma, Hodgkin Disease
Hodgkin Disease
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Sandra Jeane Horning
 Lymphoma
Lymphoma, Hodgkin Disease
Hodgkin Disease





The physicians of the Stanford Cancer Center are engaged in more than 250 clinical trials.  Contracts with some of our clinical trial sponsors prevent us from listing specific trial information on our web site. Please contact the Stanford Cancer Clinical Trials Office at 650-498-7061 for information about additional open clinical trials.

Stanford Medicine Resources:

Footer Links: